Comparative Pharmacology
Head-to-head clinical analysis: NAPHAZOLINE HYDROCHLORIDE versus PREFRIN A.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NAPHAZOLINE HYDROCHLORIDE versus PREFRIN A.
NAPHAZOLINE HYDROCHLORIDE vs PREFRIN-A
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Agonist at alpha-1 and alpha-2 adrenergic receptors, causing vasoconstriction of conjunctival blood vessels and reducing nasal mucosal congestion.
PREFRIN-A contains phenylephrine, an alpha-1 adrenergic receptor agonist, and acetaminophen, a centrally acting analgesic and antipyretic. Phenylephrine causes vasoconstriction in nasal mucosa, reducing congestion. Acetaminophen inhibits cyclooxygenase (COX) enzymes in the brain, reducing prostaglandin synthesis.
1-2 drops of 0.1% solution in each eye every 3-4 hours as needed; intranasal: 0.05% solution, 1-2 sprays per nostril every 6-8 hours.
1 drop in each affected eye every 3-4 hours as needed, not to exceed 4 times daily.
None Documented
None Documented
Approximately 2-3 hours after systemic absorption; clinical effect is limited by local vasoconstriction rather than plasma half-life.
Terminal elimination half-life: 2-4 hours in adults; 6-12 hours in neonates and infants due to immature hepatic metabolism.
Primarily renal excretion of unchanged drug and metabolites; exact % not established in humans due to limited systemic absorption after topical use. In animal studies, ~30-40% excreted unchanged in urine.
Renal: 70-80% as unchanged drug and metabolites; biliary/fecal: 20-30% as metabolites.
Category C
Category C
Ophthalmic Decongestant
Ophthalmic Decongestant/Antihistamine Combination